Akero is a startup based in the United States.
Akero Therapeutics develops novel therapies for metabolic diseases, focusing on treatments for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational drug efruxifermin (EFX).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.